Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with FR type receptors
A compound for treating cancer tumors, particularly ovarian cancer tumors, is described, where a fused cyclic pyrimidine having a cancer treating ability is effective to allow selective delivery to a cancerous tumor.
1. A compound effective in inhibiting glycinamide ribonucleotide formyltransferase (GARFTase) in cancerous tumors of a patient consisting essentially of a fused cyclic pyrimidine having the chemical formula:
wherein n=5-8; and wherein the fused cyclic pyrimidine targets primarily folate receptors (FR) expressing cancerous tumors and itself acts as a cancer treating agent and inhibits GARFTase within the tumors.
2. The compound of claim 1 wherein n=5 in the chemical formula.
3. The compound of claim 1 wherein n=6 in the chemical formula.
4. The compound of claim 1 wherein n=7 in the chemical formula.
5. The compound of claim 1 wherein n=8 in the chemical formula.
6. A method for inhibiting glycinamide ribonucleotide formyltransferase (GARFTase) in cancerous tumors of a patient comprising:
(a) providing a fused cyclic pyrimidine having the chemical formula:
where n=7-8;
(b) selectively delivering the fused cyclic pyrimidine alone to cancerous tumors, where the fused cyclic pyrimidine targets primarily folate receptor expressing (FR-expressing) cancerous tumors; and
(c) effecting entry of said fused cyclic pyrimidine into said cancerous tumors where said fused cyclic pyrimidine itself acts as a cancer treating agent and inhibits GARFTase within the tumors.
7. The method of claim 6 including wherein said fused cyclic pyrimidine is selective for receptors selected from the group consisting of folate receptor alpha (FR-alpha), folate receptor beta (FR-beta), and mixtures thereof, associated with expressing cancerous tumors.
8. The method of claim 6 including wherein said fused cyclic pyrimidine is selective for folate receptor alpha (FR-alpha) expressing cancerous cells.
9. The method of claim 6 including wherein said fused cyclic pyrimidine is not significantly taken up by a tissue or a cell using the reduced folate carrier system (RFC system).
10. The method of claim 6 including wherein said fused cyclic pyrimidine functions as a substrate of folylpolyglutamate synthetase (FPGS) in the tumors, thereby being trapped in the tumors.
11. The method of claim 6 including wherein said fused cyclic pyrimidine stays inside the cancerous tumor for an effective amount of time to kill the tumors by way of polyglutamylation and the multi ionic form of the fused pyrimidine itself.
12. The method of claim 6 including wherein said fused cyclic pyrimidine requires no separate cancer treating agent or conjugation to a separate cytotoxic agent.
13. The method of claim 6 including wherein said fused cyclic pyrimidine targets at least one advanced stage cancerous tumor.
14. The method of claim 6 including wherein said fused cyclic pyrimidine targets at least one platinum resistant cancerous tumor.
15. The method of claim 6 including wherein said fused cyclic pyrimidine targets at least one carboplatin resistant cancerous tumor.
16. The method of claim 6 including wherein said fused cyclic pyrimidine targets at least one paclitaxel resistant cancerous tumor.
17. The method of claim 6 including wherein said fused cyclic pyrimidine targets at least one docitaxel resistant cancerous tumor.
18. The method of claim 6 including wherein said fused cyclic pyrimidine is polyglutamylated by folypoly-gamma glutamate synthetase.
19. The method of claim 6 including wherein said fused cyclic pyrimidine targets cancerous tumors selected from the group consisting of ovarian, endometrial, kidney, lung, mesothelioma, breast, and brain tumors.